News & Updates

Add-on clarithromycin boosts recovery from pneumonia

13 Jan 2024

Adding clarithromycin to standard of care appears to improve clinical response and reduce inflammation in patients with community-acquired pneumonia, as reported in the phase III ACCESS trial.

Add-on clarithromycin boosts recovery from pneumonia

13 Jan 2024

Tiotropium beneficial to patients with mild COPD

12 Jan 2024

Treatment with tiotropium appears to reduce the risk of clinically important deterioration (CID) in patients with mild-to-moderate chronic obstructive pulmonary disease (COPD), including those with fewer respiratory symptoms, according to a study.

Tiotropium beneficial to patients with mild COPD

12 Jan 2024

Adjuvant alectinib benefits Asians with resected ALK+ NSCLC

09 Jan 2024 by

Adjuvant treatment with alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, significantly improved disease-free survival (DFS) better than platinum-based chemotherapy at 2 years in Asian patients with early-stage, completely resected ALK-positive non–small cell lung cancer (ALK+ NSCLC) in an exploratory analysis of the phase III ALINA trial.

Adjuvant alectinib benefits Asians with resected ALK+ NSCLC

09 Jan 2024

mRNA boosters protect cancer patients against adverse COVID-19 outcomes

08 Jan 2024 by

A prospective study from Singapore provides evidence of the clinical effectiveness of mRNA-based vaccines against COVID-19 in individuals with cancer.

mRNA boosters protect cancer patients against adverse COVID-19 outcomes

08 Jan 2024

Singapore faces high asthma burden

05 Jan 2024 by

Singapore is disproportionately burdened by asthma, with related hospitalizations and emergency department (ED) visits occurring twice as often as the average of other developed countries, according to a study.

Singapore faces high asthma burden

05 Jan 2024

Fluvoxamine of little benefit in mild-to-moderate COVID-19

02 Jan 2024

The use of fluvoxamine for outpatient treatment of mild-to-moderate COVID-19 falls short of reducing the duration of symptoms, as shown in the ACTIV-6 study.

Fluvoxamine of little benefit in mild-to-moderate COVID-19

02 Jan 2024

Severe outcomes more likely with Omicron XBB.1.16 in SG

29 Dec 2023 by

In a preliminary analysis, the risk of severe outcomes was higher in individuals infected with the Omicron XBB.1.16 subvariant compared with those who were infected with other subvariants such as the XBB.1.5 or XBB.1.9.

Severe outcomes more likely with Omicron XBB.1.16 in SG

29 Dec 2023

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

29 Dec 2023

The oral selective tyrosine kinase inhibitor sunvozertinib demonstrates therapeutic potential in patients with nonsmall cell lung cancer (NSCLC) with EGFR exon 20 insertions (exon20ins) who have previously received platinum-based chemotherapy, according to the results of a phase II WU-KONG6 study.

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

29 Dec 2023

Nocturnal reflux, snoring linked to increased risk of asthma, respiratory problems

22 Dec 2023

People with nocturnal gastroesophageal reflux (GER) and habitual snoring are vulnerable to developing asthma and respiratory symptoms, according to a study.

Nocturnal reflux, snoring linked to increased risk of asthma, respiratory problems

22 Dec 2023

Mobocertinib only as good as platinum chemo in first-line NSCLC treatment

20 Dec 2023 by

In the first-line treatment of locally advanced or metastatic nonsmall cell lung cancer (NSCLC) patients with EGFR exon 20 insertion (ex20ins) mutations, the investigational mobocertinib is safe and efficacious but not necessarily better than platinum-based chemotherapy, according to the phase III EXCLAIM-2 trial.

Mobocertinib only as good as platinum chemo in first-line NSCLC treatment

20 Dec 2023

News & Updates

Filter by Specialty:

Specialty:

Add-on clarithromycin boosts recovery from pneumonia

Add-on clarithromycin boosts recovery from pneumonia

Tiotropium beneficial to patients with mild COPD

Tiotropium beneficial to patients with mild COPD

Adjuvant alectinib benefits Asians with resected ALK+ NSCLC

Adjuvant alectinib benefits Asians with resected ALK+ NSCLC

mRNA boosters protect cancer patients against adverse COVID-19 outcomes

mRNA boosters protect cancer patients against adverse COVID-19 outcomes

Singapore faces high asthma burden

Singapore faces high asthma burden

Fluvoxamine of little benefit in mild-to-moderate COVID-19

Fluvoxamine of little benefit in mild-to-moderate COVID-19

Severe outcomes more likely with Omicron XBB.1.16 in SG

Severe outcomes more likely with Omicron XBB.1.16 in SG

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

Nocturnal reflux, snoring linked to increased risk of asthma, respiratory problems

Nocturnal reflux, snoring linked to increased risk of asthma, respiratory problems

Mobocertinib only as good as platinum chemo in first-line NSCLC treatment

Mobocertinib only as good as platinum chemo in first-line NSCLC treatment